



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/509,247	Group Art Unit:	1648
Filing Date:	September 28, 2004	Examiner:	Peng, Bo
Applicant:	Shunichi KURODA et al.		
Title:	DRUGS COMPRISING PROTEIN FORMING HOLLOW NANOPARTICLES AND THERAPEUTIC SUBSTANCE TO BE TRANSFERRED INTO CELLS FUSED THEREWITH		
Attorney Docket:	12480-000068/US		

TERMINAL DISCLAIMER

Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

October 19, 2007

Sir:

JAPAN SCIENCE AND TECHNOLOGY AGENCY, (hereinafter "the Assignee")

☐ residing at _____ , _____

☒ a corporation having a principal place of business at 1-8, Hon-cho 4-chome,
Kawaguchi-shi, Saitama 332-0012 JAPAN

☐ a university having an address of _____ , _____

represents that it is the true owner of the entire interest of U.S. Patent Application No. 10/509,247, filed on September 28, 2004, for "DRUGS COMPRISING PROTEIN FORMING HOLLOW NANOPARTICLES AND THERAPEUTIC SUBSTANCE TO BE TRANSFERRED INTO CELLS FUSED THEREWITH,"(hereinafter "above-identified application") by virtue of

10/22/2007 CNGUYEN2 00000012 000750 10509247
01 FC:1814 130.00 DA

and as evidenced by an Assignment recorded at the United States Patent and Trademark Office at Reel 016066, Frame 0447.

The Assignee hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimers of U.S. Application No. 10/220,125, U.S. Application No. 10/529,749, and U.S. Application No. 10/509,248, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal titles to U.S. Application No. 10/220,125, U.S. Application No. 10/529,749, and U.S. Application No. 10/509,248 shall be the same as the legal title to any patent issuing from the above-identified application, this agreement to run with any patent granted on the above-identified application, and to be binding upon the grantee, its successors or assigns.

The Assignee does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term as presently shortened by any terminal disclaimers of U.S. Application No. 10/220,125, U.S. Application No. 10/529,749, and U.S. Application No. 10/509,248 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Application No.10/509,247
Attorney Docket No. 12480-000068/US

This Terminal Disclaimer is submitted on behalf of the Assignee by the undersigned, an attorney of record in the above-identified application.

Please charge any fees or credit any overpayment pursuant to 37 C.F.R. § 1.20 to Deposit Account No. 08-0750.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.

By 

Donald J. Daley, Reg. No. 34,313

DJD/EGH:ald

P.O. Box 8910
Reston, VA 20195
(703)668-8000

(Rev. 01/14/05)